くすりのしおり

Injection
Published: 11/2019

The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.
Brand name :
DARBEPOETIN ALFA BS 10 mcg Syringe for Injection "SANWA"
 Active ingredient:
Darbepoetin alfa (genetical recombination) [darbepoetin alfa biosimilar 2]
 Dosage form:
injection
 Print on wrapping:

Effects of this medicine

This medicine acts on cells that grow into red blood cells (RBCs) to increase the number of RBCs and consequently improves anemia attributable to renal diseases.
It is usually used for the treatment of renal anemia.

Before using this medicine, be sure to tell your doctor and pharmacist

  • If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
    If you have a history of myocardial infarction, pulmonary infarction or cerebral infarction.
    If you have hypertension.
  • If you are pregnant or breastfeeding.
  • If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)

Dosing schedule (How to take this medicine)

  • Your dosing schedule prescribed by your doctor is ((        to be written by a healthcare professional))
  • For hemodialysis patients: In general, for adults and children, inject intravenously once per week or once every two weeks.
    For patients with chronic kidney disease not on dialysis and peritoneal dialysis patients: In general, for adults and children, inject subcutaneously or intravenously once every two or four weeks.
    In any case, ask your doctor about the dosing instructions.
  • You will be administered this medicine over a long time under the monitoring of efficacy.
  • If you use this medicine for the first time or after an interval, you may be administered lower dose intravenously or subcutaneously and observed whether any abnormalities occur.

Precautions while taking this medicine

  • You need to take iron to get an adequate efficacy. If you are prescribed iron preparation, you should take it as instructed by your doctor.
  • This medicine may cause hyperkalemia. Follow adequate dietary control.
  • If you are a patient with chronic kidney disease not on dialysis, seek direction for optimal water intake from your doctor or pharmacist and follow their instruction.

Possible adverse reactions to this medicine

The most commonly reported adverse reactions include increased blood pressure, shunt thrombosis/occlusion, headache and malaise. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
  • paralysis on one side, decreased consciousness, difficulty speaking [cerebral infarction]
  • headache, nausea, vomiting [cerebral bleeding]
  • general malaise, nausea, yellowing of the skin and the conjunctiva [liver dysfunction, jaundice]
  • dizziness, sudden severe headache, numbness of limbs [hypertensive encephalopathy]
  • facial pallor/cold sweat, respiratory distress, hives [shock, anaphylaxis]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.

Storage conditions and other information

For healthcare professional use only : Day Month Year

For further information, talk to your doctor or pharmacist.